TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
This study is ongoing, but not recruiting participants.
Study NCT00543725
Information provided by Tibotec Pharmaceuticals, Ireland
First Received: October 11, 2007
Last Updated: July 17, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
